S0776 Inpatient Outcomes in Inflammatory Bowel Disease Patients With Non-Alcoholic Fatty Liver Disease

Patel, Nisha; Pusateri, Antoinette; Hinton, Alice; Afzali, Anita

doi:10.14309/01.ajg.0000705152.63158.f6

Cited by 1 publication

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All 7 articles selected for the analysis included patient cohorts originating from American hospitals. Four studies included only inpatients with administrative data obtained from the Nationwide Readmissions Database [18,19,26] and the Nationwide Inpatient Sample Database (NIS) [25]. Three studies followed patients from initial outpatient settings, with their respective cohorts originating from US-based IBD centers [23,24,27].…”

Section: Resultsmentioning

confidence: 99%

“…Three studies did not separate patients with CD from those with ulcerative colitis (UC) (n = 1 540 583) [24–26]. Only one cohort included and evaluated CD and UC patients separately (n = 18 170 CD and n = 9866 UC patients) [19].…”

Section: Resultsmentioning

confidence: 99%

“…Four articles diagnosed NAFLD in their cohorts based on ICD coding [18,19,25,26] and two articles diagnosed the disease based on imaging findings [24,27]. Only one study failed to specify how NAFLD was diagnosed in its patient population [23].…”

Section: Resultsmentioning

confidence: 99%

“…Diagnostic codes that ascertain IBDrelatedness as a reason for admission are provided in Supplementary Material 2, Supplemental digital content 1, http://links.lww.com/EJGH/A891. Three studies did not separate patients with CD from those with ulcerative colitis (UC) (n = 1 540 583) [24][25][26]. Only one cohort included and evaluated CD and UC patients separately (n = 18 170 CD and n = 9866 UC patients) [19].…”

Section: Patient Populationmentioning

confidence: 99%

“…The first study reported a TC of −1572.96 USD; 95% CI: −4773.51 to 1627.59, P = 0.33 [25,26]. The second study reported an adjusted OR of 259; 95% CI: −787 to 1306, P = 0.627 [25,26]. However, Abomhya et al (215 049 patients) demonstrated an increase in median total hospitalization costs of 32 305.5 USD; IQR = 18 600-61 599 in NAFLD+IBD patients vs. 30 782 USD; IQR = 16 847-58 667, P < 0.001 for those with IBD alone [18].…”

Section: Hospitalization Costmentioning

confidence: 99%

See 4 more Smart Citations

The impact of nonalcoholic fatty liver disease on inflammatory bowel disease-related hospitalization outcomes: a systematic review

Boustany

Rahhal

Mitri

et al. 2023

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Evidence suggests that patients with inflammatory bowel disease are at higher risk of developing nonalcoholic fatty liver disease (NAFLD). However, there is limited information currently available on how NAFLD may affect the clinical course of IBD. Thus, we conducted a systematic review to evaluate the impact of NAFLD on IBD-related hospitalization outcomes. All observational studies assessing IBD-related hospitalization outcomes in patients with NAFLD were included. Exclusion criteria were studies published in languages other than English or French, or those involving pediatric population. Outcomes included IBD-related hospitalization and readmission rates, need for surgery, length of stay, inpatient mortality, and costs. Overall, 3252 citations were retrieved and seven studies met the inclusion criteria (1 574 937 patients); all were observational, of high quality, and originated in the United States. Measurable outcomes reported in these studies were few and with insufficient similarity across studies to complete a quantitative assessment. Only one study reports NAFLD severity. Two studies suggested a higher rate of hospitalization for patients with both NAFLD and IBD compared to IBD alone (incidence rate ratio of 1.54; 95% confidence interval: 1.33–1.79). This is the first systematic review to date that evaluates any possible association of NAFLD with IBD-related hospitalization outcomes. Despite the paucity and low quality of available data, our findings indicate that NAFLD may be associated with worse outcomes amongst IBD patients (especially Crohn’s disease). Further and higher certainty of evidence is needed for better characterization of such clinical impact.

show abstract